Investorideas.com - Biotechnology Products; UV Flu Technologies (OTC.BB: UVFT) UV-400 Air Purifier Fights Superbugs including NDM-1
"Superbugs may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant"- Dr. Wladyslaw Jan Kowalski, PE, Phd
Category: Investment, Biotech
Subscribe to Investor Ideas Newswire
Visit this company: www.uvflutech.com
CENTERVILLE, MA - September 24, 2010 (Investorideas.com newswire) - UV Flu Technologies, Inc. (OTC.BB:UVFT) reports that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: "Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish."
Dr. Kowalski further added, "The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m(2), as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route."
"Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains," said Jack Lennon, President of UV Flu Technologies. "Antibiotics have become so pervasive in today's medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived."
"So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed," said Mr. Lennon. "We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
No comments:
Post a Comment